| Net loss from operations | -9.34M |
| Loss on derivative liabilities | |
| Shares issued for technology access fee | |
| Amortization of note discount and patents | |
| Warrants issued as investment fees | |
| Depreciation | 245K |
| Stock-based compensation | 1.7M |
| Accounts receivable | 101K |
| Tax refund | |
| Accounts payable and accrued expenses | 482K |
| Prepaid expenses and other current assets | -49K |
| Interest on loan notes | |
| Net cash used in operating activities | -9.11M |
| Purchases of property and equipment | -266K |
| Net cash used in investing activities | -266K |
| Proceeds from December financings | 4.22M |
| Proceeds from Preferred Series B | |
| Proceeds from convertible loan notes | |
| Net cash provided by financing activities | 3.97M |
| Effect of exchange rates | |
| Net increase (decrease) in cash and cash equivalents | -5.4M |
| Cash and cash equivalents, beginning of period | 9.37M |
| Cash and cash equivalents, end of period | 3.97M |
| Conversion of convertible loan notes and accrued interest to Series B Convertible Preferred Stock | |